Literature DB >> 21253689

[Urine markers with special regard to fluorescent in situ hybridization (FISH)].

K Lindemann-Docter1, N T Gaisa, D Smeets, R Knüchel-Clarke.   

Abstract

Patient care with noninvasive or minimally invasive methods is appealing for the patient. It has to be assessed in terms of validity to guarantee improvement of patient care. Urine cytology for the detection of tumour cells can be considered a valid method since its specificity and sensitivity is high when high-grade tumour cells are sought. High-grade tumour cells are considered the clinically most relevant finding in urine specimens. Fluorescent in situ hybridization of interphase nuclei on centromeric and gene loci has been optimized for urothelial carcinoma and increases the sensitivity of tumour findings. It also gives a valid chance to adapt the number of cystoscopies in the follow-up of bladder cancer patients more individually.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21253689     DOI: 10.1007/s00120-010-2411-8

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  10 in total

1.  Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder.

Authors:  Hans-Martin Fritsche; Maximilian Burger; Wolfgang Dietmaier; Stefan Denzinger; Ekkehard Bach; Wolfgang Otto; Matthias Doblinger; Stephan Schwarz; Hannes Buchner; Arndt Hartmann
Journal:  Am J Clin Pathol       Date:  2010-10       Impact factor: 2.493

2.  Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria.

Authors:  Michael F Sarosdy; Paul R Kahn; Mark D Ziffer; William R Love; Jack Barkin; Emmanuel O Abara; Ken Jansz; Julia A Bridge; Sonny L Johansson; Diane L Persons; Jane S Gibson
Journal:  J Urol       Date:  2006-07       Impact factor: 7.450

3.  Fluorescence in situ hybridisation in the diagnosis of upper urinary tract tumours.

Authors:  Christine Mian; Guido Mazzoleni; Silke Vikoler; Thomas Martini; Ruth Knüchel-Clark; Dirk Zaak; Alexander Lazica; Stephan Roth; Michael Mian; Armin Pycha
Journal:  Eur Urol       Date:  2010-05-05       Impact factor: 20.096

4.  A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results.

Authors:  Raj S Pruthi; Matthew Nielsen; Samuel Heathcote; Eric M Wallen; W Kim Rathmell; Paul Godley; Young Whang; Julia Fielding; Heather Schultz; Gayle Grigson; Angela Smith; William Kim
Journal:  BJU Int       Date:  2010-01-19       Impact factor: 5.588

5.  Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.

Authors:  M Laé; J Couturier; S Oudard; F Radvanyi; P Beuzeboc; A Vieillefond
Journal:  Ann Oncol       Date:  2009-11-04       Impact factor: 32.976

6.  Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group.

Authors:  Robert Dreicer; Hailun Li; Mark Stein; Robert DiPaola; Michael Eleff; Bruce J Roth; George Wilding
Journal:  Cancer       Date:  2009-09-15       Impact factor: 6.860

Review 7.  [Cytology of the urinary tract: Between uncertainty and clarity].

Authors:  L Bubendorf; P Dalquen; S Savic
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

8.  Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.

Authors:  S Schwarz; M Rechenmacher; T Filbeck; R Knuechel; H Blaszyk; A Hartmann; G Brockhoff
Journal:  J Clin Pathol       Date:  2007-08-10       Impact factor: 3.411

Review 9.  [Urine-based tumour diagnostics for bladder cancer: effects of the new histopathological classification--food for thought].

Authors:  R Knüchel; K Lindemann-Docter
Journal:  Urologe A       Date:  2009-06       Impact factor: 0.639

Review 10.  Bladder tumor markers: a review of the literature.

Authors:  A Volpe; M Racioppi; D D'Agostino; E Cappa; M Gardi; A Totaro; F Pinto; E Sacco; F Marangi; G Palermo; P F Bassi
Journal:  Int J Biol Markers       Date:  2008 Oct-Dec       Impact factor: 3.248

  10 in total
  2 in total

Review 1.  [Urine cytology - update 2013. A systematic review of recent literature].

Authors:  M Böhm; F vom Dorp; M Schostak; O W Hakenberg
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

Review 2.  [Cytology in uropathological diagnostics].

Authors:  N T Gaisa; K Lindemann-Docter
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.